MaaT Pharma, RB, Gelita and Clasado


MaaT Pharma moved swiftly to appoint Claude Bertrand, as member to the French firm’s board of directors, who also introduced Dr John Weinberg, as MaaT Pharma’s new chief medical officer.

“John has a proven track record of guiding and managing clinical development programs for microbiome therapeutics which will be critical as we accelerate the development of MaaT013 and expand our portfolio with our capsule formulation, MaaT033,”​ commented Hervé Affagard, MaaT Pharma’s co-founder and CEO.

Weinberg’s previously held the position of chief medical officer at the microbiome firm 4D Pharma, where he oversaw the clinical development program and initiating Phase I/II studies.

With over 25 years’ experience primarily in the pharmaceutical industry, he has held senior positions at Veloxis Pharmaceuticals, Novartis Pharmaceuticals and Enzon Pharmaceuticals.

Commenting on his appointment, Dr Weinberg said, “I am very excited to join as the company is poised to expand its therapeutic focus beyond haematological cancer indications. My goal is to define an innovative clinical development program and contribute to the continued growth of the pipeline.”

 “I look forward to working alongside my fellow board members to guide and support the development of the company and its exciting pipeline,”​ added Dr Bertrand.

RB hire

Another company making a change to its executive committee is Reckitt Benckiser (RB), which earlier this month made Angela Naef its new chief research & development officer.


Please enter your comment!
Please enter your name here